Download PDF
Thromb Haemost 1984; 51(03): 317-320
DOI: 10.1055/s-0038-1661091
Original Article
Schattauer GmbH Stuttgart

Correction of Clotting Factor “Deficiencies” in Plasma from Patients with Lupus-Like Anticoagulants

Lionel P Clyne
The Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, the Department of Pathology, VA Medical Center, West Haven, CT, and the Departments of Biomedical Research and Medicine, St. Elizabeth’s Hospital of Boston and Tufts University, School of Medicine, Boston, MA, U.S.A.
,
Christine L Honig
The Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, the Department of Pathology, VA Medical Center, West Haven, CT, and the Departments of Biomedical Research and Medicine, St. Elizabeth’s Hospital of Boston and Tufts University, School of Medicine, Boston, MA, U.S.A.
,
Nicholas Dainiak
The Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, the Department of Pathology, VA Medical Center, West Haven, CT, and the Departments of Biomedical Research and Medicine, St. Elizabeth’s Hospital of Boston and Tufts University, School of Medicine, Boston, MA, U.S.A.
› Author Affiliations
Further Information

Publication History

Received 30 May 1983

Accepted 09 February 1984

Publication Date:
19 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Identification of spurious coagulation factor deficiencies that are known to occur in association with lupus-like anticoagulants (LLACs) requires the use of cumbersome laboratory procedures. To determine whether single-stage assays employing the APTT system may be used to identify such artifacts, we measured multiple clotting factor levels by several techniques in plasma of six patients with typical LLACs. While normal activities of factors VIII, IX, XI and XII were measured in only 4/24 APTT assays (17%) employing human plasma substrate, normal factor activities were present in all 24 APTT assays employing bovine, canine or rabbit plasma substrate. Normal factor II, V and X activities were recorded in all but one case in assays that utilized a modified Stypven time, while normal factor VIII levels were determined in 5/6 plasmas when the thromboplastin generation test was employed. These results indicate that the use of heterologous plasma substrates in the APTT system may provide a simple method to identify such coagulation factor “deficiencies”.

Keywords

Heterologous substrates - Lupus inhibitors - Coagulation factor assays
 

  • References

  • 1 Conley CL, Hartman RC. A hemorrhagic disorder caused by circulating anticoagulants in patients with disseminated lupus erythematosus. J Clin Invest 1952; 31: 621-622
    PubMedSearch in Google Scholar
  • 2 Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. Prog Hemostas Thromb 1972; 1: 75-95
    PubMedSearch in Google Scholar
  • 3 Yin ET, Gaston LW. Purification and kinetic studies on a circulating anticoagulant in a suspected case of lupus erythematosus. Thrombos Diathes Haemorrh 1965; 14: 88-115
    PubMedSearch in Google Scholar
  • 4 Lechner K. Acquired inhibitors in nonhemophilic patients. Haemostasis 1974; 3: 65-93
    PubMedSearch in Google Scholar
  • 5 Schleider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the lupus anticoagulant. Blood 1976; 48: 499-509
    PubMedSearch in Google Scholar
  • 6 Shapiro SS, Hutlin M. Acquired inhibitors to the blood coagulation factors. Semin Thromb Hemostas 1975; 1: 336-385
    PubMedSearch in Google Scholar
  • 7 Clyne LP, Dainiak N, Hoffman R, Hardin JA. In vitro correction of anticoagulant activity and specific clotting factor assays in SLE. Thromb Res 1980; 18: 643-655
    CrossrefPubMedSearch in Google Scholar
  • 8 Veltkamp JJ, Kerkhoven P, Loeliger EA. Circulating anticoagulant in disseminated lupus erythematosus. Proposed mode of action Haemostasis 1973/74 2: 253-259
    PubMed
  • 9 Bowie EJ W, Thompson JH, Paschuzzi CA, Owen CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 1963; 62: 416-430
    PubMedSearch in Google Scholar
  • 10 Mueh JR, Herbst KD, Rapaport SI. Thrombosis in patients with the lupus anticoagulant. Ann Intern Med 1980; 92: 156-159
    CrossrefPubMedSearch in Google Scholar
  • 11 Cohen AS, Reynolds WE, Franklin EC, Kulka JO, Ropes MW, Shulman LE, Wallace SL. Preliminary criteria for the classification of systemic lupus erythematosus. Bull Rheum Dis 1971; 21: 643-645
    PubMedSearch in Google Scholar
  • 12 Zarrabi MH, Zucker S, Miller F, Derman RM, Romano GS, Hartnett JA, Varma AO. Immunologic and coagulation disorders in chlorpromazine treated patients. Ann Intern Med 1979; 91: 194-199
    CrossrefPubMedSearch in Google Scholar
  • 13 Proctor PR, Rapaport SI. The partial thromboplastin time with kaolin. Am J Clin Pathol 1961; 36: 212-219
    CrossrefPubMedSearch in Google Scholar
  • 14 Bell WN, Alton HG. A brain extract as a substitute for platelet suspensions in the thromboplastin generation test. Nature 1954; 174: 880-881
    CrossrefPubMedSearch in Google Scholar
  • 15 Pool JG, Robinson J. Assay of plasma antihaemophilic globulin (AHG). Br J Haematol 1959; 5: 17-23
    CrossrefPubMedSearch in Google Scholar
  • 16 Müller-Berghaus G, Lasch HG. Consumption of Hageman factor activity in the generalized Shwartzman reaction induced by liquoid. Thrombos Diathes Haemorrh 1970; 23: 386-404
    PubMedSearch in Google Scholar
  • 17 Exner T, Rickard KA, Kronenbert H. A sensitive test demonstrating lupus anticoagulant and its behavioral patterns. Br J Haematol 1978; 40: 143-151
    CrossrefPubMedSearch in Google Scholar
  • 18 Loeliger A. Prothrombin as co-factor of the circulating anticoagulant in systemic lupus erythematosus. Thrombos Diathes Haemorrh 1959; 3: 237-256
    PubMedSearch in Google Scholar
  • 19 Rivard GE, Schiffman S, Rapaport SI. Cofactor of the “Lupus anticoagulant”. Thrombos Diathes Haemorrh 1974; 32: 554-563
    PubMedSearch in Google Scholar
  • 20 Dodds WJ. Second Int’l Registry of Animal Models of Thrombosis and Hemorrhagic Diseases. Nat’l Acad Press; Washington D.C.: 1981. 24 4-25
    Search in Google Scholar
  • 21 Hougie C. Naturally occurring species specific inhibitor of human prothrombin in lupus erythematosus. Proc Soc Exp Biol Med 1964; 116: 359-361
    CrossrefPubMedSearch in Google Scholar
  • 22 Gonyea L, Herdman R, Bridges RA. The coagulation abnormalities in systemic lupus erythematosus. Thrombos Diathes Haemorrh 1968; 20: 457-464
    PubMedSearch in Google Scholar
  • 23 Castro O, Farber LR, Clyne LP. Circulating anticoagulants against factors IX and XI in systemic lupus erythematosus. Ann Intern Med 1972; 77: 543-548
    CrossrefPubMedSearch in Google Scholar
  • 24 DiSabatino CA, Clyne LP, Malawista SE. A circulating anticoagulant directed against factor XI a in systemic lupus erythematosus. Arth Rheum 1979; 22: 1135-1138
    CrossrefPubMedSearch in Google Scholar